Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4543330 | 1.00 | MEN1 (0.38) | MEN1KMT2ACHRNA7CYP2D6CYP19A1 | |
| Piperazine SCHEMBL28179364 | 1.00 | MEN1 (0.38) | MEN1KMT2ACHRNA7CYP2D6CYP19A1 | |
| SCHEMBL13509549 | 1.00 | MEN1 (0.38) | MEN1KMT2ACHRNA7CYP2D6CYP19A1 | |
| SCHEMBL5387 | 0.97 | — | — | |
| SCHEMBL77101 | 0.97 | — | — | |
| SCHEMBL1706403 | 0.97 | MEN1 (0.39) | MEN1KMT2ACHRNA7CYP2D6CYP19A1 | |
| Hydrochloric Acid SCHEMBL522550 | 0.94 | MEN1 (0.38) | MEN1KMT2ACHRNA7CYP2D6CYP19A1 | |
| Hydrochloric Acid SCHEMBL1742546 | 0.94 | MEN1 (0.38) | MEN1KMT2ACHRNA7CYP2D6CYP19A1 | |
| Iodide SCHEMBL30375035 | 0.94 | MEN1 (0.38) | MEN1KMT2ACHRNA7CYP2D6CYP19A1 | |
| SCHEMBL4822887 | 0.94 | MEN1 (0.38) | MEN1KMT2ACHRNA7CYP2D6CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023076598-A1 | LIPID AMINES | MODERNATX, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20200138982-A1 | RADIOACTIVE PROBE FOR DETECTING HYDROGEN SULFIDE | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY- ACADEMIC COOPERATION FOUNDATION (KR) | 2020-05-07 | — | — | US | disclosed |
| US-20180045705-A1 | METHODS OF MEASURING HYDROGEN SULFIDE CONCENTRATIONS IN RESERVOIR FLUIDS | SHELL OIL COMPANY | 2018-02-15 | — | — | US | disclosed |
| US-20160304473-A1 | EXCIMER FORMING COMPOUNDS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2016-10-20 | — | — | US | disclosed |
| US-9314468-B2 | Chemokine receptor modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20130172330-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-8338448-B2 | Chemokine receptor modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-7985745-B2 | Including inflammatory pain, post surgical pain, and neuropathic pain; administering a histamine H4 receptor ligand alone or in combination with a histamine H1, H2, or H3 receptor antagonist or an enzyme inhibitor | ABBOTT LABORATORIES (US) | 2011-07-26 | — | — | US | disclosed |
| US-20100029634-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | MKI67, CCNI, CDKN1A | MEN1 173/4885KMT2A 682/4885CHRNA7 4830/4885 |
| US-20200138982-A1 | RADIOACTIVE PROBE FOR DETECTING HYDROGEN SULFIDE | TST, SCLY, CTH | MEN1 2360/4885KMT2A 4261/4885CHRNA7 4635/4885 |
| US-20130172330-A1 | Chemokine Receptor Modulators | CCR5, CXCR4, ACKR3 | MEN1 2799/4885KMT2A 4546/4885CHRNA7 3228/4885 |
| US-20160304473-A1 | EXCIMER FORMING COMPOUNDS | PHAX, RNMT, POLM | MEN1 2014/4885KMT2A 4495/4885CHRNA7 4098/4885 |
| US-20100029634-A1 | Chemokine Receptor Modulators | CCR5, CXCR4, ACKR3 | MEN1 2799/4885KMT2A 4546/4885CHRNA7 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.